Research
Hormonal
GLP-1 receptor agonists (specifically liraglutide and semaglutide) improve histological features of NASH and achieve resolution of NASH without worsening fibrosis in adults with or without type 2 diabetes.
If you have NASH, GLP-1 agonists like semaglutide or liraglutide are proven to improve liver health, potentially resolving the disease without worsening scarring. They are taken as injections (daily or weekly). While they can cause nausea, the liver benefits are substantial, especially if you have type 2 diabetes or obesity. Consult your doctor for dosing.
GoodSupportsHIGH confidence
GLP-1R agonists (mostly liraglutide and semaglutide) improved individual histological features of NASH (eg, steatosis, ballooning, lobular inflammation) or achieved resolution of NASH without worsening of fibrosis.
Why this rating
Based on a systematic review of 25 RCTs, though many were small and short-term.
Source
Glucagon-like Peptide-1 Agonists
Peter Y. W. Chan et al. · JBJS Reviews · 2024
DOI 10.2106/jbjs.rvw.23.00167
systematic_review · n=2597Cited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →